Target $30.50 is wildly below current price $296.64 — this target is clearly a data entry error (appears to be a remnant). BD acquisition integration risk + near-term refinancing headwinds. Cannot score reliably without corrected target. Downgrade to 4 pending full re-analysis to reset target price.
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
32.4%/yr
±4.3% · revenue growth to justify current price
FCF-Based Reverse DCF
39.7%/yr
±3.6% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~6h).
Eagle will generate this view by the next trading session (~6h).
Waters completes .8B BD Biosciences acquisition (Feb 2026). Transforms from pure analytical instruments to diversified life sciences platform. B new debt requires Q1 2026 refinancing. M revenue + M co...